Brain radiation showdown: which technique saves your memory?
NCT ID NCT07505979
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests three radiation approaches for people with six or more brain metastases from solid tumors. One group gets focused high-dose radiation (SRS), while the other two get whole-brain radiation with memory-sparing techniques plus a drug called memantine. The goal is to see which treatment best preserves cognitive function at six months. Ninety participants will be tracked with memory tests and brain scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiation therapy (SRS or WBRT) plus memantine
What this could lead to
If successful, this trial could identify which radiation approach best protects memory and thinking in patients with multiple brain metastases.
What could go wrong
This is a small, early-phase trial (90 people) comparing three treatments, so results may not apply broadly. Radiation can still cause cognitive side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES FROM SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••